Pirtobrutinib and CAR T-cell therapy for mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mantle cell lymphoma that has returned or not improved after other treatments.
- You are 18 years or older and healthy enough for daily activities (ECOG score 0-2).
- You have not had CAR T-cell therapy before.
- You have not taken pirtobrutinib for more than 2 months previously, or if you did, it was only as a short-term holding therapy and your lymphoma did not get worse on it.
- Your key lab tests (blood counts, liver, kidney, heart, and lung function) are within acceptable ranges.
- You agree to use effective birth control if applicable, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
This trial tests a combination of two targeted drugs (sonrotoclax and zanubrutinib) given before your planned CAR-T cell therapy. The goal is to see if this approach can help control the lymphoma while you wait for CAR-T.
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
This study tests a type of immunotherapy called CAR-T cells (modified immune cells) for people with untreated, high-risk mantle cell lymphoma. It aims to see if this therapy can help control the disease early on.
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.